News

FDA Approves the First Immunotherapy Drug for Childhood Leukemia

FDA Approves the First Immunotherapy Drug for Childhood Leukemia

The FDA approved a new drug therapy for pediatric leukemia that uses immunotherapy, or the re-engineering of a person’s own T cells to enable them to fight cancer. “This therapy has been really so successful; 93 percent of children here on our trial with this therapy have gone into full remission. These are children who had previously been resistant to lots of different kinds of chemotherapy, so this is really an exciting result,” said Dr. Colleen Annesley, a pediatric oncologist at Seattle Children’s Hospital.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.